Frontiers in Oncology最新文献

{"title":"Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.","authors":"Edgar Yebran Villegas-Vazquez, Francisco Pável Marín-Carrasco, Octavio Daniel Reyes-Hernández, Andrea S Báez-González, Lilia Patricia Bustamante-Montes, Teresita Padilla-Benavides, Laura Itzel Quintas-Granados, Gabriela Figueroa-González","doi":"10.3389/fonc.2024.1514120","DOIUrl":"10.3389/fonc.2024.1514120","url":null,"abstract":"<p><p>Drug repositioning, the practice of identifying novel applications for existing drugs beyond their originally intended medical indications, stands as a transformative strategy revolutionizing pharmaceutical productivity. In contrast to conventional drug development approaches, this innovative method has proven to be exceptionally effective. This is particularly relevant for cancer therapy, where the demand for groundbreaking treatments continues to grow. This review focuses on drug repositioning for ovarian cancer treatment, showcasing a comprehensive exploration grounded in thorough <i>in vitro</i> experiments across diverse cancer cell lines, which are validated through preclinical <i>in vivo</i> models. These insights not only shed light on the efficacy of these drugs but also expand in potential synergies with other pharmaceutical agents, favoring the development of cost-effective treatments for cancer patients.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1514120"},"PeriodicalIF":3.5,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: The impact of alkalizing the acidic tumor microenvironment to improve efficacy of cancer treatment, volume II.","authors":"Reo Hamaguchi, Noha Mousaad Elemam, Shinji Uemoto, Hiromi Wada","doi":"10.3389/fonc.2024.1542787","DOIUrl":"10.3389/fonc.2024.1542787","url":null,"abstract":"","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1542787"},"PeriodicalIF":3.5,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum stromal cell-derived factor 1α as a prognostic indicator in elderly patients with acute myeloid leukemia receiving CAG-based chemotherapy.","authors":"Zhenzhen Wang, Jing Yuan, Nan Zhou, Jianfeng Zhang","doi":"10.3389/fonc.2024.1521179","DOIUrl":"10.3389/fonc.2024.1521179","url":null,"abstract":"<p><strong>Background: </strong>Stromal-cell-derived factor 1 (SDF-1) plays a crucial role in hematopoiesis and has been implicated in acute myeloid leukemia (AML) pathogenesis. Understanding its relationship with chemotherapy outcomes could lead to improved therapeutic approaches for elderly AML patients.</p><p><strong>Methods: </strong>This study retrospectively analyzed the medical records of elderly AML patients (n = 187) and compared serum SDF-1α levels with age-matched controls (n = 120). Patients received CAG (cytarabine, aclarubicin, and G-CSF)-based chemotherapy, and serum SDF-1α levels were assessed using ELISA.</p><p><strong>Results: </strong>Serum SDF-1α levels were significantly elevated in elderly AML patients compared to controls (p < 0.001). Receiver operating characteristic (ROC) analysis confirmed its diagnostic relevance, revealing the area under the ROC curve (AUC) of 0.76. Factors such as age, French-American-British (FAB) classification, Eastern Cooperative Oncology Group (ECOG) performance status, primary AML status, white blood cell count, and bone marrow blast cell ratio, were confirmed to be prognostically relevant. Serum SDF-1α levels were elevated in patients who did not achieve complete remission (NCR) compared to those in complete remission (CR). ROC analysis further highlighted the predictive capability of serum SDF-1α for chemotherapy responsiveness. Independent predictors of treatment failure included age, FAB classification, ECOG status, and serum SDF-1α levels. Following chemotherapy, serum SDF-1α levels decreased in patients in CR but remained unchanged in those in NCR. Higher baseline levels of SDF-1α were associated with shorter overall survival.</p><p><strong>Conclusions: </strong>Elevated serum SDF-1α levels in elderly AML patients are associated with poor chemotherapy response and shorter survival. Baseline serum SDF-1α levels could serve as a prognostic marker for CAG-based treatment outcomes.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1521179"},"PeriodicalIF":3.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Intra-abdominal inflammatory myofibroblastic tumor with mucinous features: a case of rapid recurrence and dissemination post-surgery.","authors":"Xingchen Li, Jie Li, Chunxiao Liang, Qing Zou","doi":"10.3389/fonc.2024.1517710","DOIUrl":"10.3389/fonc.2024.1517710","url":null,"abstract":"<p><p>Inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal neoplasms with intermediate biological potential and are characterized by spindle-shaped myofibroblastic cells and significant inflammatory infiltrates. This case report describes a 24-year-old male with diabetes who was admitted to the hospital for over three days of vomiting and abdominal pain and was initially diagnosed with diabetic ketoacidosis. Upon admission, an abdominal CT scan revealed a large cystic-solid mass in the abdominal cavity and multiple nodules in the mesentery, omentum, and peritoneum, suggesting a preliminary diagnosis of an intra-abdominal mesenchymal tumor with peritoneal metastasis. The patient underwent tumor resection, and postoperative pathology confirmed it to be an IMT rich in mucin, with a Ki-67 proliferation index of 50%. Despite the initial symptom improvement after surgery, the patient experienced rapid recurrence with more extensive abdominal lesions. The patient refused further treatment, and died shortly thereafter. The case underscores the aggressive nature of inflammatory myofibroblastic tumors (IMTs) characterized by significant mucinous features, which are prone to recurrence and may suggest a poor prognosis. Radiological examinations and preoperative fine-needle aspiration biopsy may play a crucial role in managing such cases. Furthermore, alternative non-surgical treatment options or adjunct postoperative treatments could have a positive impact on the prognosis of this patient group. Further research is vital for enhancing our understanding of this rare tumor type and optimizing treatment strategies.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1517710"},"PeriodicalIF":3.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brucea javanica oil inhibited the proliferation, migration, and invasion of oral squamous carcinoma by regulated the MTFR2 pathway.","authors":"Yihan Lai, Mingkang Li, Juan Zhan, Lin Jiang, Yuan Wu, Zhiyi Fang, Jianhan Zhou, Yujie Ma, Yisen Shao, Wei Wang","doi":"10.3389/fonc.2024.1477293","DOIUrl":"10.3389/fonc.2024.1477293","url":null,"abstract":"<p><strong>Introduction: </strong>Oral squamous cell carcinoma (OSCC) is one of the most common malignant tumors in oral and maxillofacial region. The development of new chemotherapy agents and new drug combinations may improve patient survival and quality of life, but both surgery and radiotherapy have significant functional side effects and drug resistance, ultimately resulting in a 5-year survival rate of no more than 60% for OSCC patients. Studies have shown that Brucea javanica oil (BJO) extracts have anti-cancer effects against a variety of cancers, but little research has been reported on OSCC.</p><p><strong>Methods: </strong>CCK8, Colony formation, Scratch test and Transwell invasion assays were applied to determine the effects of BJO on the proliferation, migration, and invasion ability of OSCC cells in vitro. MTFR2 knockdown (shRNA) and overexpression (cDNA) OSCC cells were constructed to evaluate the effect of MTFR2 on the proliferation and invasion of OSCC cells. The nude mouse model of subcutaneous xenograft tumor was used to evaluate the effect of BJO on OSCC cells <i>in vivo</i>. PCR, western blot and immunohistochemistry were used to verify the expression of MTFR2, glycolysis markers and related pathway molecules after BJO treatment.</p><p><strong>Results: </strong><i>In vivo</i> experiments using nude mice with xenografted OSCC cells and <i>in vitro</i> experiments with OSCC cell lines demonstrated that BJO treatment significantly inhibited the proliferation, migration, and invasiveness of OSCC cells. WB and PCR proved that BJO could effectively reduce the expression levels of MTFR2 and SOD2/H2O2 related signal transduction pathways. At the same time, the expression of oxidative phosphorylation markers increased, the expression of glycolytic markers decreased, and glycolysis-mediated decomposition of reactive oxygen species decreased, and H2O2 and oxygen levels decreased.In addition, when MTFR2 expression increased or decreased, SOD2/H2O2 expression also increased or decreased.</p><p><strong>Discussion: </strong>In this study, we concluded through in vitro and in vivo experiments that BJO may affect the SOD2/H2O2 signaling pathway by down-regulating MTFR2-mediated aerobic glycolysis, thereby inhibiting cell proliferation, Migration, and Invasion. The elucidation of this mechanism helps us to understand the molecular mechanism ofinhibiting OSCC invasion and metastasis by BJO, which has important clinical value or improving the survival rate of OSCC patients.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1477293"},"PeriodicalIF":3.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric schwannoma with post-surgical gastroparesis: a case report and literature review.","authors":"Ganggang Miao, De Zhang, Jiajing Li, Yanxiang Deng, Xingwei Gu, Tingting Feng","doi":"10.3389/fonc.2024.1496074","DOIUrl":"10.3389/fonc.2024.1496074","url":null,"abstract":"<p><p>Gastric schwannoma is a relatively rare submucosal mesenchymal tumor with low probability of metastasis and arises from Schwann cells of the gastrointestinal nervous plexus. Surgical therapy is the main treatment of gastric schwannoma with symptoms or malignant tendency. Gastroparesis is a potential complication following gastrointestinal surgery, which is a clinical syndrome caused by gastric emptying disorder and characterized by nausea, vomiting, and bloating, resulting in insufficient nutrient intake. Generally, post-surgical etiology is the main potential etiology of gastroparesis, while the most common underlying etiology is diabetes mellitus. So far, reports of gastroparesis arising from resection of gastric schwannoma are rare. We present an 80-year-old woman who was diagnosed with gastrointestinal stromal tumor (GIST) primarily and has undergone laparoscopic wedge-shaped gastrectomy. The pathological and immunohistochemical examination ultimately established the diagnosis of gastric schwannoma. The patient experienced belching, nausea, vomiting, and bloating 1 week after the surgery and confirmed as gastroparesis through gastrointestinal series and gastroscopic examination. A series of treatments were performed, including correcting fluid-electrolyte disorders and vitamin deficiencies, and nutritional support and pharmacological treatments. The patient ultimately recovered well, and the relevant literatures were reviewed to identify and handle similar cases hereafter.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1496074"},"PeriodicalIF":3.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative analysis of ferroptosis in the hypoxic microenvironment of gastric cancer unveils the immune landscape and personalized therapeutic strategies.","authors":"Xiao Xu, Liangling Fa, Xiaoxiao Sun, Fangfang Yang, Yongrui Liu, Jifu Song, Yongli Zhao, Jigang Dong","doi":"10.3389/fonc.2024.1499580","DOIUrl":"10.3389/fonc.2024.1499580","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis is a cell death mode caused by excessive accumulation of lipid peroxides caused by disturbance of intracellular metabolic pathway, which is closely related to iron and cholesterol metabolism homeostasis. Its regulation within the hypoxic metabolic tumor microenvironment (TME) has the potential to improve the effectiveness of tumor immunotherapy. The predictive role of ferroptosis in gastric cancer (GC) hypoxia TME, particularly in relation to TME immune cell infiltration, has not been fully explained.</p><p><strong>Methods: </strong>By analyzing the mRNA expression data of ferroptosis and hypoxia-related genes, a prediction model was constructed to evaluate further the predictive value of immune cell infiltration, clinical characteristics, and immunotherapy efficacy of gastric cancer, and the essential genes were validated.</p><p><strong>Results: </strong>Two distinct molecular states of ferroptosis-hypoxia were identified in GC. Notably, patients with high ferroptosis-hypoxia risk scores (FHRS) displayed significant levels of hypoxia and epithelial-mesenchymal transition (EMT), which were associated with unfavorable prognosis, increased chemoresistance, and heightened immunosuppression.</p><p><strong>Conclusions: </strong>This study demonstrates that ferroptosis under hypoxic conditions significantly affects the modulation of the tumor immune microenvironment. The FHRS can independently predict prognosis in gastric cancer. Assessing the molecular status of ferroptosis-hypoxia in individual patients will help in selecting more suitable immunotherapy regimens by providing a better understanding of TME characteristics and predicting immunotherapeutic outcomes.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1499580"},"PeriodicalIF":3.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning based models for predicting presentation delay risk among gastric cancer patients.","authors":"Huali Zhou, Qiong Gu, Rong Bao, Liping Qiu, Yuhan Zhang, Fang Wang, Wenlian Liu, Lingling Wu, Li Li, Yihua Ren, Lei Qiu, Qian Wang, Gaomin Zhang, Xiaoqing Qiao, Wenjie Yuan, Juan Ren, Min Luo, Rong Huang, Qing Yang","doi":"10.3389/fonc.2024.1503047","DOIUrl":"10.3389/fonc.2024.1503047","url":null,"abstract":"<p><strong>Objective: </strong>Presentation delay of cancer patients prevents the patient from timely diagnosis and treatment leading to poor prognosis. Predicting the risk of presentation delay is crucial to improve the treatment outcomes. This study aimed to develop and validate prediction models of presentation delay risk in gastric cancer patients by using various machine learning models.</p><p><strong>Methods: </strong>875 cases of gastric cancer patients admitted to a tertiary oncology hospital from July 2023 to June 2024 were used as derivation cohort, 200 cases of gastric cancer patients admitted to other 4 tertiary hospital were used as external validation cohort. After collecting the data, statistical analysis was performed to identify discriminative variables for the prediction of presentation delay and 13 statistically significant variables are selected to develop machine learning models. The derivation cohort was randomly assigned to the training and internal validation set by the ratio of 7:3. Prediction models were developed based on six machine learning algorithms, which are logistic regression (LR), support vector machine (SVM), random forest (RF), gradient boosted trees (GBDT), extremely gradient boosting (XGBoost) and muti-layer perceptron (MLP). The discrimination and calibration of each model were assessed based on various metrics including accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), F1-Score and area under curve (AUC), calibration curves and Brier scores. The best model was selected based on comparing of various metrics. Based on the selected best model, the impact of features to the prediction result was analyzed with the permutation feature importance method.</p><p><strong>Results: </strong>The incidence of presentation delay for gastric cancer patients was 39.3%. The developed models achieved performance metrics as AUC (0.893-0.925), accuracy (0.817-0.847), sensitivity (0.857-0.905), specificity (0.783-0.854), PPV (0.728-0.798), NPV (0.897-0.927), F1 score (0.791-0.826) and Brier score (0.107-0.138) in internal validation set, which indicated good discrimination and calibration for the prediction of presentation delay in gastric cancer patients. Among all models, RF based model was selected as the best one as it achieved good discrimination and calibration performance on both of internal and external validation set. Feature ranking results indicated that both of subjective and objective factors have significant impact on the occurrence of presentation delay in gastric cancer patients.</p><p><strong>Conclusion: </strong>This study demonstrated that the RF based model has favorable performance for the prediction of presentation delay in gastric cancer patients. It can help medical staffs to screen out high-risk gastric cancer patients for presentation delay, and to take appropriate and specific interventions to reduce the risk of presentation delay.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1503047"},"PeriodicalIF":3.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of VANGL2 in glioma oncogenesis and progression: insights into expression profiles and prognostic relevance.","authors":"Mingyu Zhao, Shanshuang Chen","doi":"10.3389/fonc.2024.1527226","DOIUrl":"10.3389/fonc.2024.1527226","url":null,"abstract":"<p><strong>Introduction: </strong>The Wnt/planar cell polarity (PCP) signaling pathway is pivotal in regulating various biological processes such as early embryonic development, neural crest cell migration, and cancer invasion. Despite advances in understanding the role of Wnt/PCP pathway dysregulation in tumorigenesis, numerous unanswered questions remain. Our study focused on VANGL2, a core PCP gene, to elucidate its potential mechanistic involvement in cancer development.</p><p><strong>Methods: </strong>A systematic analysis was conducted to assess VANGL2 expression patterns at both transcriptional and proteomic levels. Functional enrichment analysis was performed to investigate the biological pathways associated with VANGL2 in glioma. <i>In vitro</i> experiments were conducted to assess the impact of VANGL2 on glioma cell behaviors. Furthermore, rigorous methodologies were employed in survival analysis to control for confounding factors.</p><p><strong>Results: </strong>We identified substantial upregulation of VANGL2 gene in both low-grade glioma (LGG) and glioblastoma (GBM). Functional enrichment analysis of genes positively associated with VANGL2 in glioma underscored their enrichment in Notch signaling and pathway regulating pluripotency of stem cells. <i>In vitro</i> experiments further confirmed that VANGL2 promotes glioma cell migration, invasion, proliferation, and tumor sphere formation. We identified a significant correlation between increased VANGL2 expression and IDH mutation in glioma patients. Elevated VANGL2 expression was identified as a predictor of poor prognosis in glioma.</p><p><strong>Conclusion: </strong>Our analysis of the expression and prognostic features of the core PCP gene VANGL2 underscored its critical roles in glioma oncogenesis and progression.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1527226"},"PeriodicalIF":3.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic and diagnostic value of circRNA expression in cervical cancer: a meta analysis.","authors":"Yi Xu, Changxia Li, Lifang Cheng, Shaoheng Wang, Yuqing Wu, Shiyang Li, Mingqiang Liu, Xiaohua Tao","doi":"10.3389/fonc.2024.1488040","DOIUrl":"10.3389/fonc.2024.1488040","url":null,"abstract":"<p><strong>Introduction: </strong>Cervical cancer (CC) is a highly prevalent malignancy of the reproductive system. This study aimed to methodically assess the function of circular RNAs (circRNAs) as possible indicators of CC, with a specific emphasis on their usefulness in the identification, prediction, and correlation with clinicopathological elements.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted using databases such as PubMed, Cochrane Library, Web of Science, Embase, and the China National Knowledge Infrastructure (CNKI). The latest data were extracted on May 3^rd, 2024. The diagnostic potential of circRNA expression was evaluated using a range of metrics including sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). The importance of circRNAs was further evaluated in terms of clinical relevance, pathological features, and prognostic value using pooled odds ratios (ORs) and hazard ratios (HRs).</p><p><strong>Results: </strong>The meta-analysis included 27 studies, which were categorised based on diagnostic applications (n=3), clinicopathological correlations (n=15), and prognostic evaluations (n=23). Elevated expression levels of oncogenic circRNAs were significantly associated with poor clinical indicators, including tumour size (odds ratio [OR] = 0.425, 95% confidence interval [CI]: 0.267-0.676), International Federation of Gynaecology and Obstetrics (FIGO) stage (OR = 0.315, 95% CI: 0.224-0.443), and lymph node metastasis (OR = 2.975, 95% CI: 1.816-4.872). This upregulation of oncogenic circRNA was also identified as a predictor of worse survival outcomes, with a hazard ratio (HR) of 2.13 (95% CI: 1.73-2.62, <i>P</i> < 0.001). The downregulation of circRNAs with tumour-suppressor properties was similarly associated with poor clinical parameters, such as tumour size (OR = 0.310, 95% CI: 0.102-0.941), FIGO stage (OR = 0.231, 95% CI: 0.101-0.527), and lymph node metastasis (OR = 2.430, 95% CI: 1.156-5.110), and was indicative of a worsened prognosis (HR = 2.20, 95% CI: 1.03-4.70, <i>P</i> = 0.042). In terms of diagnostic value, the pooled sensitivity, specificity, and area under the curve (AUC) were calculated to be 0.85, 0.83, and 0.91, respectively.</p><p><strong>Conclusion: </strong>The results of our meta-analysis indicate that circRNAs have the potential to serve as promising biomarkers for CC diagnosis, prognosis, and clinicopathology.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024544997.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1488040"},"PeriodicalIF":3.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}